(EMAILWIRE.COM, January 23, 2019 ) The immunohistochemistry market is projected to reach USD 2.12 billion by 2021, growing at a CAGR of 7.3% during the forecast period. Rising geriatric population, growing prevalence of chronic diseases, rapid technological developments in the IVD industry, and increasing healthcare spending are expected to fuel the growth of this market in the coming years. However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine are expected to offer significant growth opportunities for players in the immunohistochemistry market. Regulatory restrictions in developed countries, however, are a major challenge faced by market players in the current immunohistochemistry market.

Immunohistochemistry market is categorized into two application segments, namely, diagnostics and drug testing. The global immunohistochemistry market for diagnostic applications is further segmented into infectious diseases, cancer, cardiovascular diseases, diabetes, autoimmune diseases, and nephrological diseases. In 2015, the diagnostics segment accounted for the largest share of the global immunohistochemistry market. The large share of this segment is attributed to growing prevalence of cancer, and wide application of immunohistochemistry in the diagnosis of cancers, infectious diseases,
cardiovascular diseases, and other diseases.

Sample Report - https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939

North America dominates the global immunohistochemistry market, and this trend is expected to continue during the forecast period. The large share of North America can be attributed to the fact that the majority of big players operating in the immunohistochemistry market are located in this region. In addition, the increasing geriatric population and rising incidence of chronic diseases like cancer, infectious diseases, and cardiovascular disease in this region are expected to boost the market for diagnostics.

Key Players
The major players in the immunohistochemistry market are F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck Millipore (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abcam plc (U.K.), Cell Signaling Technology, Inc. (U.S.), and Bio SB Inc. (U.S.).